Skip to content

Scailyte Quarterly Update December 2021

Scailyte’s quarterly report December 2021 on the progress towards its mission to save millions of lives

Scailyte quarterly update

Scailyte quarterly update, highlighting the successful first closing of the Series A financing round and the three new patents filed on the discoveries. Scailyte has appointed a new Chief Operating Officer with executive pharma background, Corinne Solier. Here is a quote from Corinne – “The next revolution will be realized when we can fully harness the power of single-cell biological information to discover new and more sensitive biomarkers of diagnostic, predictive and prognostic value for individual patients. Scailyte’s perfectly suited capabilities, as well as the passionate and excellent team, convinced me to join the company, to fulfil our mission of advancing precision medicine.” Read more below:

Read our previous quarterly update here

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. 

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Scailyte closes Series A funding with a CHF 6 million investment

Scailyte has successfully finished the Series A funding raising CHF 6 million from a Swiss family of

Read more

Recent News

VACANCY: Internship in Women’s Health R&D

The internship in Women’s Health R&D will focus on our in vitro diagnostics development work in en

Read more

Recent News

Nilogen and Scailyte Are Joining Forces to Find the “Right” Treatment for Every Patient

Nilogen and Scailyte are joining forces to increase the success of cancer therapies in clinics and t

Read more

Recent News

Machine learning meets multi-omics for precision medicine

Bringing industry and academia together to discuss the potential impact of single-cell analytics pow

Read more

Recent News

Understanding Resistant to CAR-T Immunotherapy to Develop Better Next-generation Therapies

Register for Scailyte's webinar on "Understanding Resistant to CAR-T Immunotherapy to Develop Better

Read more

Recent News

VACANCY: Technical Lead / Product Owner for a clinical diagnostic software

Scailyte is a globally recognised spin-off from ETH Zürich and a pioneer in the field of single-cel

Read more

Recent News

VACANCY: Data Scientist in Biomarker Discovery

Scailyte is a globally recognized spin-off from ETH Zürich and a pioneer in the field of single-cel

Read more

Recent News

True precision medicine through single-cell science - Nature

ScaiVision identifies disease signatures predicting drug efficacy & drug mode of action. Precision m

Read more

Recent News

01 /04

Scailyte closes Series A funding with a CHF 6 million investment

Scailyte has successfully finished the Series A funding raising CHF 6 million from a Swiss family of

Read more

VACANCY: Internship in Women’s Health R&D

The internship in Women’s Health R&D will focus on our in vitro diagnostics development work in en

Read more

Recent News

02 /04

Nilogen and Scailyte Are Joining Forces to Find the “Right” Treatment for Every Patient

Nilogen and Scailyte are joining forces to increase the success of cancer therapies in clinics and t

Read more

Machine learning meets multi-omics for precision medicine

Bringing industry and academia together to discuss the potential impact of single-cell analytics pow

Read more

Recent News

03 /04

Understanding Resistant to CAR-T Immunotherapy to Develop Better Next-generation Therapies

Register for Scailyte's webinar on "Understanding Resistant to CAR-T Immunotherapy to Develop Better

Read more

VACANCY: Technical Lead / Product Owner for a clinical diagnostic software

Scailyte is a globally recognised spin-off from ETH Zürich and a pioneer in the field of single-cel

Read more

Recent News

04 /04

VACANCY: Data Scientist in Biomarker Discovery

Scailyte is a globally recognized spin-off from ETH Zürich and a pioneer in the field of single-cel

Read more

True precision medicine through single-cell science - Nature

ScaiVision identifies disease signatures predicting drug efficacy & drug mode of action. Precision m

Read more

Recent News